数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Timothy S. Callahan Director 46 17.42万美元 未持股 2017-04-28
Thomas H. Adams Director 74 17.22万美元 未持股 2017-04-28
Melvin K. Spigelman Director 68 18.57万美元 未持股 2017-04-28
Melvin K. Spigelman Director 68 未披露 未持股 2017-04-28
Alan F. Joslyn Director 58 16.12万美元 未持股 2017-04-28
John P. Brancaccio Director 69 18.91万美元 未持股 2017-04-28
Gary S. Jacob Chairman, President, Chief Executive Officer 70 255.02万美元 未持股 2017-04-28
Richard J. Daly Director 56 17.04万美元 未持股 2017-04-28

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Patrick Griffin Executive Vice President and Chief Medical Officer 61 未披露 未持股 2017-04-28
Troy Hamilton Executive Vice President and Chief Commercial Officer 45 109.52万美元 未持股 2017-04-28
Marino Garcia Executive Vice President and Chief Strategy Officer 50 未披露 未持股 2017-04-28
Patrick Griffin Executive Vice President and Chief Medical Officer 61 113.53万美元 未持股 2017-04-28
Gary G. Gemignani Executive Vice President and Chief Financial Officer 51 未披露 未持股 2017-04-28
Kunwar Shailubhai Chief Scientific Officer 59 158.45万美元 未持股 2017-04-28
Bernard F. Denoyer Senior Vice President, Finance, Secretary 69 59.50万美元 未持股 2017-04-28
Gary S. Jacob Chairman, President, Chief Executive Officer 70 255.02万美元 未持股 2017-04-28

董事简历

中英对照 |  中文 |  英文
Timothy S. Callahan

Timothy S. Callahan,他是我们公司的董事(2015年6月以来)。他是一个全球性的生命科学商业领袖,拥有21年以上的制药和生物转化经验,最近任职Actavis组织。2013年至2014年,他曾担任高级副总裁,负责商业运营,在那里他曾担任领导Actavis品牌业务成为每年70亿美元的部门,专注于胃肠病学、女性健康、泌尿外科、皮肤科,以及其它专业市场。2010年至2012年,他曾担任Actavis公司的国际品牌和生物制品销售副总裁。2003年至2009年,他曾担任公司的肾脏学部门的销售与市场副总裁。职业生涯早期,他曾担任Watson Pharmaceuticals、Schein Pharmaceutical的商业领导职务,并不断被提拔。他也曾就读于Cornell University,并持有应用经济学和商业管理科学学士学位。他拥有胃肠病学专业产品开发丰富经验,这使他有资格担任我们公司的董事。


Timothy S. Callahan has served as a director of the company's since June 2015. Mr. Callahan is a global life sciences business leader with over 21 years of experience in pharmaceutical and biologic commercialization, most recently with the Actavis organization. From 2013-2014 he served as Senior Vice President, Commercial Operations where he played a leadership role in the transformation of the Actavis brand business into a $7B/year division with a focus in Gastroenterology, Women’s Health, Urology, Dermatology, and other specialty markets. From 2010-2012 Mr. Callahan served as Vice President, International Brands & Biologics Marketing at Actavis, and from 2003-2009 he served as Vice President, Sales & Marketing for the company’s Nephrology division. Earlier in his career, Mr. Callahan held positions of increasing responsibility in commercial leadership at Watson Pharmaceuticals and Schein Pharmaceutical. Mr. Callahan was educated at Cornell University and holds a Bachelor of Science degree in Applied Economics and Business Management.
Timothy S. Callahan,他是我们公司的董事(2015年6月以来)。他是一个全球性的生命科学商业领袖,拥有21年以上的制药和生物转化经验,最近任职Actavis组织。2013年至2014年,他曾担任高级副总裁,负责商业运营,在那里他曾担任领导Actavis品牌业务成为每年70亿美元的部门,专注于胃肠病学、女性健康、泌尿外科、皮肤科,以及其它专业市场。2010年至2012年,他曾担任Actavis公司的国际品牌和生物制品销售副总裁。2003年至2009年,他曾担任公司的肾脏学部门的销售与市场副总裁。职业生涯早期,他曾担任Watson Pharmaceuticals、Schein Pharmaceutical的商业领导职务,并不断被提拔。他也曾就读于Cornell University,并持有应用经济学和商业管理科学学士学位。他拥有胃肠病学专业产品开发丰富经验,这使他有资格担任我们公司的董事。
Timothy S. Callahan has served as a director of the company's since June 2015. Mr. Callahan is a global life sciences business leader with over 21 years of experience in pharmaceutical and biologic commercialization, most recently with the Actavis organization. From 2013-2014 he served as Senior Vice President, Commercial Operations where he played a leadership role in the transformation of the Actavis brand business into a $7B/year division with a focus in Gastroenterology, Women’s Health, Urology, Dermatology, and other specialty markets. From 2010-2012 Mr. Callahan served as Vice President, International Brands & Biologics Marketing at Actavis, and from 2003-2009 he served as Vice President, Sales & Marketing for the company’s Nephrology division. Earlier in his career, Mr. Callahan held positions of increasing responsibility in commercial leadership at Watson Pharmaceuticals and Schein Pharmaceutical. Mr. Callahan was educated at Cornell University and holds a Bachelor of Science degree in Applied Economics and Business Management.
Thomas H. Adams

Thomas H. Adams自2009年4月起担任董事会主席,自2018年6月起担任我们的首席执行官。他目前是Hepion Pharmaceuticals,Inc。的董事,自2014年以来一直担任该职位。此前,Adams博士曾担任董事长。于2013年至2019年担任成像解决方案公司Clearbridge BioPhotonics,Inc。的职位,并于2009年至2019年担任Synergy Pharmaceuticals,Inc。的总监。他曾在IRIS International担任过多个领导职务,包括董事,个性化医学主管和首席技术官。从2005年到2012年被Danaher Corporation收购该公司的官员。从1998年到2006年,Adams博士是Leucadia Technologies的董事长兼首席执行官,该公司是一家私有生物技术公司,于2006年被IRIS International,Inc。收购。 Adams于1989年创立了Genta,Inc.,并担任首席执行官直到1997年。他还于1984年成立了Gen-Probe,Inc.,并担任了董事长兼首席执行官。 1989年被Chugai Biopharmaceuticals,Inc。收购。Adams博士拥有博士学位。加州大学里弗赛德分校生物化学专业。


Thomas H. Adams has served as Chairman of the Board since April 2009 and as our Chief Executive Officer since June 2018. He is currently a Director at Hepion Pharmaceuticals, Inc. where he has served since 2014. Previously, Dr. Adams served as Chairman of Clearbridge BioPhotonics, Inc., an imaging solutions company, from 2013 to 2019 and as Director of Synergy Pharmaceuticals, Inc. from 2009 to 2019. He served in several leadership roles at IRIS International, including Director, Head of Personalized Medicine and Chief Technology Officer, from 2005 until the company's acquisition by Danaher Corporation in 2012. From 1998 to 2006 Dr. Adams was Chairman and Chief Executive Officer of Leucadia Technologies, a privately held biotechnology company which was acquired by IRIS International, Inc. in 2006. Dr. Adams founded Genta, Inc. in 1989 and served as its Chief Executive Officer until 1997. He also founded Gen-Probe, Inc. in 1984 and served as Chairman and Chief Executive Officer until its acquisition by Chugai Biopharmaceuticals, Inc. in 1989. Dr. Adams holds a Ph.D. in Biochemistry from the University of California, Riverside.
Thomas H. Adams自2009年4月起担任董事会主席,自2018年6月起担任我们的首席执行官。他目前是Hepion Pharmaceuticals,Inc。的董事,自2014年以来一直担任该职位。此前,Adams博士曾担任董事长。于2013年至2019年担任成像解决方案公司Clearbridge BioPhotonics,Inc。的职位,并于2009年至2019年担任Synergy Pharmaceuticals,Inc。的总监。他曾在IRIS International担任过多个领导职务,包括董事,个性化医学主管和首席技术官。从2005年到2012年被Danaher Corporation收购该公司的官员。从1998年到2006年,Adams博士是Leucadia Technologies的董事长兼首席执行官,该公司是一家私有生物技术公司,于2006年被IRIS International,Inc。收购。 Adams于1989年创立了Genta,Inc.,并担任首席执行官直到1997年。他还于1984年成立了Gen-Probe,Inc.,并担任了董事长兼首席执行官。 1989年被Chugai Biopharmaceuticals,Inc。收购。Adams博士拥有博士学位。加州大学里弗赛德分校生物化学专业。
Thomas H. Adams has served as Chairman of the Board since April 2009 and as our Chief Executive Officer since June 2018. He is currently a Director at Hepion Pharmaceuticals, Inc. where he has served since 2014. Previously, Dr. Adams served as Chairman of Clearbridge BioPhotonics, Inc., an imaging solutions company, from 2013 to 2019 and as Director of Synergy Pharmaceuticals, Inc. from 2009 to 2019. He served in several leadership roles at IRIS International, including Director, Head of Personalized Medicine and Chief Technology Officer, from 2005 until the company's acquisition by Danaher Corporation in 2012. From 1998 to 2006 Dr. Adams was Chairman and Chief Executive Officer of Leucadia Technologies, a privately held biotechnology company which was acquired by IRIS International, Inc. in 2006. Dr. Adams founded Genta, Inc. in 1989 and served as its Chief Executive Officer until 1997. He also founded Gen-Probe, Inc. in 1984 and served as Chairman and Chief Executive Officer until its acquisition by Chugai Biopharmaceuticals, Inc. in 1989. Dr. Adams holds a Ph.D. in Biochemistry from the University of California, Riverside.
Melvin K. Spigelman

Melvin K. Spigelman,从2005年9月开始担任公司董事。 从2009年1月开始,他担任Global Alliance公司结核药物开发总裁和首席执行官,这是一家推进速效和可负担的对抗结核病的药物开发的非盈利性组织。从2003年6月到2009年1月,他在Global Alliance公司结核药开发部担任研究开发总监。在加入Global Alliance公司结核药开发部之前,从2001年6月到2003年6月,他是Hudson-Douglas有限责任公司(Hudson-Douglas Ltd)总裁,这是一家咨询公司。从2000年到2001年,他是Knoll制药公司(Knoll Pharmaceuticals)全球临床中心副总裁,这是BASF制药公司的一个制药单元;从1992年到2000年,他是Knoll公司研究开发副总裁。他在Synergy制药公司(Synergy Pharmaceuticals Inc)担任董事,在那里他担任审计和薪酬委员会成员,外部交流监管委员会主席。他在布朗大学(Brown University)得到工程学士学位,在西奈山医学院(The Mount Sinai School of Medicine)得到医学博士。


Melvin K. Spigelman has been a director since September 2005. Since January 2009 Dr. Spigelman has served as president and chief executive officer of the Global Alliance for TB Drug Development, a non-profit organization which seeks to accelerate the discovery and development of faster-acting and affordable drugs to fight tuberculosis. From June 2003 to January 2009 Dr. Spigelman served as director of research and development of the Global Alliance for TB Drug Development. Before joining the Global Alliance for TB Drug Development, Dr. Spigelman was the president of Hudson-Douglas Ltd, a consulting company, from June 2001 to June 2003. From 2000 to 2001 Dr. Spigelman served as a vice president, global clinical centers at Knoll Pharmaceuticals, a pharmaceutical unit of BASF Pharma, and from 1992 to 2000 Dr. Spigelman was the vice president of research and development at Knoll. Dr. Spigelman serves as a director of Synergy Pharmaceuticals Inc., where he is a member of the audit and compensation committees and chair of the external communications oversight committee. Dr. Spigelman received a B.A. in engineering from Brown University and an M.D. from The Mount Sinai School of Medicine.
Melvin K. Spigelman,从2005年9月开始担任公司董事。 从2009年1月开始,他担任Global Alliance公司结核药物开发总裁和首席执行官,这是一家推进速效和可负担的对抗结核病的药物开发的非盈利性组织。从2003年6月到2009年1月,他在Global Alliance公司结核药开发部担任研究开发总监。在加入Global Alliance公司结核药开发部之前,从2001年6月到2003年6月,他是Hudson-Douglas有限责任公司(Hudson-Douglas Ltd)总裁,这是一家咨询公司。从2000年到2001年,他是Knoll制药公司(Knoll Pharmaceuticals)全球临床中心副总裁,这是BASF制药公司的一个制药单元;从1992年到2000年,他是Knoll公司研究开发副总裁。他在Synergy制药公司(Synergy Pharmaceuticals Inc)担任董事,在那里他担任审计和薪酬委员会成员,外部交流监管委员会主席。他在布朗大学(Brown University)得到工程学士学位,在西奈山医学院(The Mount Sinai School of Medicine)得到医学博士。
Melvin K. Spigelman has been a director since September 2005. Since January 2009 Dr. Spigelman has served as president and chief executive officer of the Global Alliance for TB Drug Development, a non-profit organization which seeks to accelerate the discovery and development of faster-acting and affordable drugs to fight tuberculosis. From June 2003 to January 2009 Dr. Spigelman served as director of research and development of the Global Alliance for TB Drug Development. Before joining the Global Alliance for TB Drug Development, Dr. Spigelman was the president of Hudson-Douglas Ltd, a consulting company, from June 2001 to June 2003. From 2000 to 2001 Dr. Spigelman served as a vice president, global clinical centers at Knoll Pharmaceuticals, a pharmaceutical unit of BASF Pharma, and from 1992 to 2000 Dr. Spigelman was the vice president of research and development at Knoll. Dr. Spigelman serves as a director of Synergy Pharmaceuticals Inc., where he is a member of the audit and compensation committees and chair of the external communications oversight committee. Dr. Spigelman received a B.A. in engineering from Brown University and an M.D. from The Mount Sinai School of Medicine.
Melvin K. Spigelman

Melvin K. Spigelman,2008年8月起担任公司董事;2009年1月起担任总裁和首席执行官;2003年6月至2008年12月担任非盈利机构TB Drug Development的全球联盟研发部主管,该机构致力于加速发现和开发快速和可负担的对抗肺结核的药物。2001年6月至2003年6月,他是咨询公司Hudson-Douglas Ltd的总裁。2000至2001年,他担任BASF Pharma的制药业务单元Knoll Pharmaceuticals的全球临床中心副总裁;1992至2000年担任Knoll研发部副总裁。2005年9月起,他也是The Medicines Company的董事。他获有Brown University 工程学学士学位,以及The Mount Sinai School of Medicine医学博士学位。


Melvin K. Spigelman has served as a director of the company's since August 2008. Since January 2009 Dr. Spigelman has served as President and CEO and from June 2003 to December 2008 as Director of Research and Development for the Global Alliance for TB Drug Development, a non-profit organization which seeks to accelerate the discovery and development of faster-acting and affordable drugs to fight tuberculosis. Dr. Spigelman was President of Hudson-Douglas Ltd, a consulting company, from June 2001 to June 2003. From 2000 to 2001 Dr. Spigelman served as a Vice President, Global Clinical Centers at Knoll Pharmaceuticals, a pharmaceutical unit of BASF Pharma, and from 1992 to 2000 Dr. Spigelman was the Vice President of Research and Development at Knoll. Dr. Spigelman has been a director of The Medicines Company since September 2005. Dr. Spigelman received a B.A. in engineering from Brown University and an M.D. from The Mount Sinai School of Medicine.
Melvin K. Spigelman,2008年8月起担任公司董事;2009年1月起担任总裁和首席执行官;2003年6月至2008年12月担任非盈利机构TB Drug Development的全球联盟研发部主管,该机构致力于加速发现和开发快速和可负担的对抗肺结核的药物。2001年6月至2003年6月,他是咨询公司Hudson-Douglas Ltd的总裁。2000至2001年,他担任BASF Pharma的制药业务单元Knoll Pharmaceuticals的全球临床中心副总裁;1992至2000年担任Knoll研发部副总裁。2005年9月起,他也是The Medicines Company的董事。他获有Brown University 工程学学士学位,以及The Mount Sinai School of Medicine医学博士学位。
Melvin K. Spigelman has served as a director of the company's since August 2008. Since January 2009 Dr. Spigelman has served as President and CEO and from June 2003 to December 2008 as Director of Research and Development for the Global Alliance for TB Drug Development, a non-profit organization which seeks to accelerate the discovery and development of faster-acting and affordable drugs to fight tuberculosis. Dr. Spigelman was President of Hudson-Douglas Ltd, a consulting company, from June 2001 to June 2003. From 2000 to 2001 Dr. Spigelman served as a Vice President, Global Clinical Centers at Knoll Pharmaceuticals, a pharmaceutical unit of BASF Pharma, and from 1992 to 2000 Dr. Spigelman was the Vice President of Research and Development at Knoll. Dr. Spigelman has been a director of The Medicines Company since September 2005. Dr. Spigelman received a B.A. in engineering from Brown University and an M.D. from The Mount Sinai School of Medicine.
Alan F. Joslyn

Alan F. Joslyn,2009年10月起担任公司董事。2011年8月起,他担任Sentinella Pharmaceuticals的药物开发顾问。2009年8月至2011年8月,他担任民营生物科技公司Edusa Pharmaceuticals的首席执行官。2007至2009年,他担任Mt. Cook Pharma的总裁和首席执行官。2004至2007年担任Penwest Pharmaceuticals研发部高级副总裁。1995至2004年间,他在Johnson & Johnson拥有多个领导职位,主要负责肠胃病药品的开发,包括Propulsid、 Motilium、Aciphex,以及prucalopride。他获有State University of New York at Buffalo医药化学专业理学士和生物学文学学士学位,以及生化药理学博士学位。他在肠胃病和产品开发方面的丰富经验,使得他胜任公司董事。


Alan F. Joslyn has served as a director of the company's since October 2009. Since June 2016 he has served as Chief Executive Officer and director of Oragenics, Inc. Since April 2014 Dr. Joslyn has been a partner in Lazarus Pharmaceuticals, LLC. From March 2010 to April 2014 Dr. Joslyn was a drug development consultant to Sentinella Pharmaceuticals. From August 2009 to October 2012 Dr. Joslyn served as the Chief Executive Officer of Edusa Pharmaceuticals, a privately held biotechnology company. From March 2007 to March 2009 Dr. Joslyn served as President and Chief Executive Officer of Mt. Cook Pharma and as Senior Vice President of Research & Development at Penwest Pharmaceuticals from 2004 to 2007. From 1995 to 2004 Dr. Joslyn held a number of leadership positions within Johnson & Johnson focusing on development of gastroenterology products including Propulsid®, Motilium®, Aciphex® and prucalopride. Dr. Joslyn received his B.S. in medicinal chemistry, B.A. in biology and Ph.D. in biochemical pharmacology from the State University of New York at Buffalo.
Alan F. Joslyn,2009年10月起担任公司董事。2011年8月起,他担任Sentinella Pharmaceuticals的药物开发顾问。2009年8月至2011年8月,他担任民营生物科技公司Edusa Pharmaceuticals的首席执行官。2007至2009年,他担任Mt. Cook Pharma的总裁和首席执行官。2004至2007年担任Penwest Pharmaceuticals研发部高级副总裁。1995至2004年间,他在Johnson & Johnson拥有多个领导职位,主要负责肠胃病药品的开发,包括Propulsid、 Motilium、Aciphex,以及prucalopride。他获有State University of New York at Buffalo医药化学专业理学士和生物学文学学士学位,以及生化药理学博士学位。他在肠胃病和产品开发方面的丰富经验,使得他胜任公司董事。
Alan F. Joslyn has served as a director of the company's since October 2009. Since June 2016 he has served as Chief Executive Officer and director of Oragenics, Inc. Since April 2014 Dr. Joslyn has been a partner in Lazarus Pharmaceuticals, LLC. From March 2010 to April 2014 Dr. Joslyn was a drug development consultant to Sentinella Pharmaceuticals. From August 2009 to October 2012 Dr. Joslyn served as the Chief Executive Officer of Edusa Pharmaceuticals, a privately held biotechnology company. From March 2007 to March 2009 Dr. Joslyn served as President and Chief Executive Officer of Mt. Cook Pharma and as Senior Vice President of Research & Development at Penwest Pharmaceuticals from 2004 to 2007. From 1995 to 2004 Dr. Joslyn held a number of leadership positions within Johnson & Johnson focusing on development of gastroenterology products including Propulsid®, Motilium®, Aciphex® and prucalopride. Dr. Joslyn received his B.S. in medicinal chemistry, B.A. in biology and Ph.D. in biochemical pharmacology from the State University of New York at Buffalo.
John P. Brancaccio

John P. Brancaccio,已退休的注册会计师;2005年12月起,担任本公司董事。他从2004年4月起,担任Accelerated Technologies的首席财务官,这是医疗器械公司的孵化器。他目前是Tamir Biotechnology(原Alfacell Corporation)、Synergy Pharmaceuticals、ContraVir Pharmaceuticals(Synergy的子公司)的董事。


John P. Brancaccio a retired CPA, has served as a director of our Company since May 15 2013. Mr. Brancaccio was the Chief Financial Officer of Accelerated Technologies, Inc., an incubator for medical device companies from April 2004 until May 2017. Mr. Brancaccio served as a director for Callisto Pharmaceuticals, Inc. from April 2004 until its merger with Synergy Pharmaceuticals, Inc. in January 2013 and was formerly a director of Tamir Biotechnology, Inc. formerly Alfacell Corporation since April 2004 until May 2020. He is also a director of Cardiff Oncology, Inc. since December 2005 Rasna Therapeutics, Inc. since September 2016 OKYO Pharma Limited since June 2020 and Tiziana Life Sciences plc since July 2020. Mr. Brancaccio served as a director of Synergy from July 2008 until April 2019.
John P. Brancaccio,已退休的注册会计师;2005年12月起,担任本公司董事。他从2004年4月起,担任Accelerated Technologies的首席财务官,这是医疗器械公司的孵化器。他目前是Tamir Biotechnology(原Alfacell Corporation)、Synergy Pharmaceuticals、ContraVir Pharmaceuticals(Synergy的子公司)的董事。
John P. Brancaccio a retired CPA, has served as a director of our Company since May 15 2013. Mr. Brancaccio was the Chief Financial Officer of Accelerated Technologies, Inc., an incubator for medical device companies from April 2004 until May 2017. Mr. Brancaccio served as a director for Callisto Pharmaceuticals, Inc. from April 2004 until its merger with Synergy Pharmaceuticals, Inc. in January 2013 and was formerly a director of Tamir Biotechnology, Inc. formerly Alfacell Corporation since April 2004 until May 2020. He is also a director of Cardiff Oncology, Inc. since December 2005 Rasna Therapeutics, Inc. since September 2016 OKYO Pharma Limited since June 2020 and Tiziana Life Sciences plc since July 2020. Mr. Brancaccio served as a director of Synergy from July 2008 until April 2019.
Gary S. Jacob

Gary S. Jacob。 Gary S. Jacob博士自2009年2月起担任公司董事。自2008年7月以来,Jacob博士一直担任Synergy Pharmaceuticals Inc.的总裁,首席执行官和董事,并担任该公司的董事。 主席自2013年9月起。雅各布博士自2013年5月起担任ContraVir Pharmaceuticals,Inc.的董事长。雅各博士于2004年10月起担任Callisto Pharmaceuticals,Inc.的董事,直至2013年1月与Synergy Pharmaceuticals,Inc.合并。 1999年之前,Jacob博士担任孟山都科学研究员,专攻糖生物学领域,1997年至1998年,他担任孟山都公司的功能基因组学,企业科学与技术总监。 雅各博士获得了B.S。 在密苏里大学化学,并拥有博士学位。 来自威斯康星大学麦迪逊分校的生物化学专业。


Gary S. Jacob,has served as Chief Executive Officer and a director of Okyo Pharma Limited since January 2021. From November 2018 to March 2020, Dr. Jacob was the Chief Executive Officer of Immuron Limited, an Australian microbiome biopharmaceutical company. From July 2008 until December 2017, Dr. Jacob was President and Chief Executive Officer of Synergy Pharmaceuticals Inc., a biopharmaceutical company, where he held various positions from July 2008 to November 2018 and he served as its Chairman from September 2013 to November 2018. On December 12, 2018, Synergy Pharmaceuticals Inc. filed a petition for relief under Chapter 11 of the U.S. Bankruptcy Code. Since March 19, 2014, Dr. Jacob has been Chairman of the Board of Hepion Pharmaceuticals, Inc., a biotechnology company, and earlier served as its Chief Executive Officer from May 15, 2013 until March 19, 2014. Dr. Jacob served as Chief Executive Officer of Callisto Pharmaceuticals, Inc. from May 2003 until January 2013 and a director from October 2004 until January 2013. Dr. Jacob also serves as a director of Rasna Therapeutics, Inc., and is a past director of Cardiff Oncology, Inc. Dr. Jacob has over 35 years of experience in the pharmaceutical and biotechnology industries across multiple disciplines including research & development, operations and business development. Prior to 1999, Dr. Jacob served as a Monsanto Science Fellow, specializing in the field of glycobiology, and from 1997 to 1998 Dr. Jacob was Director of Functional Genomics, Corporate Science & Technology, at Monsanto Company. Dr. Jacob also served from 1990 to 1997 as Director of Glycobiology at G.D. Searle Pharmaceuticals Inc. During the period of 1986 to 1990, he was Manager of the G.D. Searle Glycobiology Group at Oxford University, England.
Gary S. Jacob。 Gary S. Jacob博士自2009年2月起担任公司董事。自2008年7月以来,Jacob博士一直担任Synergy Pharmaceuticals Inc.的总裁,首席执行官和董事,并担任该公司的董事。 主席自2013年9月起。雅各布博士自2013年5月起担任ContraVir Pharmaceuticals,Inc.的董事长。雅各博士于2004年10月起担任Callisto Pharmaceuticals,Inc.的董事,直至2013年1月与Synergy Pharmaceuticals,Inc.合并。 1999年之前,Jacob博士担任孟山都科学研究员,专攻糖生物学领域,1997年至1998年,他担任孟山都公司的功能基因组学,企业科学与技术总监。 雅各博士获得了B.S。 在密苏里大学化学,并拥有博士学位。 来自威斯康星大学麦迪逊分校的生物化学专业。
Gary S. Jacob,has served as Chief Executive Officer and a director of Okyo Pharma Limited since January 2021. From November 2018 to March 2020, Dr. Jacob was the Chief Executive Officer of Immuron Limited, an Australian microbiome biopharmaceutical company. From July 2008 until December 2017, Dr. Jacob was President and Chief Executive Officer of Synergy Pharmaceuticals Inc., a biopharmaceutical company, where he held various positions from July 2008 to November 2018 and he served as its Chairman from September 2013 to November 2018. On December 12, 2018, Synergy Pharmaceuticals Inc. filed a petition for relief under Chapter 11 of the U.S. Bankruptcy Code. Since March 19, 2014, Dr. Jacob has been Chairman of the Board of Hepion Pharmaceuticals, Inc., a biotechnology company, and earlier served as its Chief Executive Officer from May 15, 2013 until March 19, 2014. Dr. Jacob served as Chief Executive Officer of Callisto Pharmaceuticals, Inc. from May 2003 until January 2013 and a director from October 2004 until January 2013. Dr. Jacob also serves as a director of Rasna Therapeutics, Inc., and is a past director of Cardiff Oncology, Inc. Dr. Jacob has over 35 years of experience in the pharmaceutical and biotechnology industries across multiple disciplines including research & development, operations and business development. Prior to 1999, Dr. Jacob served as a Monsanto Science Fellow, specializing in the field of glycobiology, and from 1997 to 1998 Dr. Jacob was Director of Functional Genomics, Corporate Science & Technology, at Monsanto Company. Dr. Jacob also served from 1990 to 1997 as Director of Glycobiology at G.D. Searle Pharmaceuticals Inc. During the period of 1986 to 1990, he was Manager of the G.D. Searle Glycobiology Group at Oxford University, England.
Richard J. Daly

Richard J. Daly,加入Catalyst Pharmaceuticals, Inc.。2015年2月加入董事会。Daly先生目前担任CARsgen Therapeutics公司(一家新兴的肿瘤学公司,专注于开发用于液体和实体肿瘤的CAR-T疗法)的总裁。从2018年7月到2022年1月,Daly先生担任BeyondSpring Pharmaceuticals的首席运营官,这是一家商业化前的生物技术公司,专注于肿瘤学,资产处于后期3期临床试验。在2018年8月加入BeyondSpring之前,(i) 2016年2月至2018年7月,Daly先生担任Neuralstem, Inc.(一家专注于基于其神经干细胞技术开发中枢神经系统疗法的生物制药公司)的董事长兼首席执行官,(ii) 2014年10月至2016年9月,Daly先生担任RavineRock Partners的合伙人,RavineRock Partners是一家专注于生物技术和制药的商业咨询公司,以及(iii) 2013年2月至2014年9月。Daly先生曾担任AstraZeneca US Diabetes总裁。从2018年到2023年该公司被出售,Daly先生担任Opiant Pharmaceuticals的董事会成员,并担任董事会薪酬和审计委员会成员。从2015年6月到2018年6月,Daly先生还担任Synergy Pharmaceuticals的董事会成员,在那里他担任提名/公司治理委员会主席,并担任薪酬委员会成员。他于1983年获得the University of Notre Dame的微生物学学士学位,并于1998年获得the Kellogg School of Management, Northwestern University的工商管理硕士学位。


Richard J. Daly,joined Catalyst Pharmaceuticals, Inc. Board in February 2015. Mr. Daly currently serves as President of CARsgen Therapeutics Corporation, an emerging oncology company focused on developing CAR-T therapies for both liquid and solid tumors. From July 2018 through January 2022, Mr. Daly served as Chief Operating Officer of BeyondSpring Pharmaceuticals, a pre-commercial biotech company focused on oncology with assets in late Phase 3 clinical trials. Before joining BeyondSpring in August 2018, (i) from February 2016 to July 2018 Mr. Daly served as Chairman and CEO of Neuralstem, Inc., a biopharmaceutical company focused on the development of central nervous system therapies based on its neuronal stem cell technology, (ii) from October 2014 to September 2016, Mr. Daly served as a partner of RavineRock Partners, a commercial consulting practice focused on biotech and pharmaceuticals, and (iii) from February 2013 to September 2014, Mr. Daly served as President of AstraZeneca US Diabetes. Mr. Daly served on the board of directors of Opiant Pharmaceuticals, and as a member of that board's Compensation and Audit Committees, from 2018 until the sale of that company in 2023. From June 2015 to June 2018 Mr. Daly also served on the Board of Directors of Synergy Pharmaceuticals, where he chaired the Nominations/Corporate Governance Committee and was a member of the Compensation Committee. Mr. Daly received his Bachelor of Science in Microbiology from the University of Notre Dame in 1983 and his MBA from the Kellogg School of Management, Northwestern University in 1998.
Richard J. Daly,加入Catalyst Pharmaceuticals, Inc.。2015年2月加入董事会。Daly先生目前担任CARsgen Therapeutics公司(一家新兴的肿瘤学公司,专注于开发用于液体和实体肿瘤的CAR-T疗法)的总裁。从2018年7月到2022年1月,Daly先生担任BeyondSpring Pharmaceuticals的首席运营官,这是一家商业化前的生物技术公司,专注于肿瘤学,资产处于后期3期临床试验。在2018年8月加入BeyondSpring之前,(i) 2016年2月至2018年7月,Daly先生担任Neuralstem, Inc.(一家专注于基于其神经干细胞技术开发中枢神经系统疗法的生物制药公司)的董事长兼首席执行官,(ii) 2014年10月至2016年9月,Daly先生担任RavineRock Partners的合伙人,RavineRock Partners是一家专注于生物技术和制药的商业咨询公司,以及(iii) 2013年2月至2014年9月。Daly先生曾担任AstraZeneca US Diabetes总裁。从2018年到2023年该公司被出售,Daly先生担任Opiant Pharmaceuticals的董事会成员,并担任董事会薪酬和审计委员会成员。从2015年6月到2018年6月,Daly先生还担任Synergy Pharmaceuticals的董事会成员,在那里他担任提名/公司治理委员会主席,并担任薪酬委员会成员。他于1983年获得the University of Notre Dame的微生物学学士学位,并于1998年获得the Kellogg School of Management, Northwestern University的工商管理硕士学位。
Richard J. Daly,joined Catalyst Pharmaceuticals, Inc. Board in February 2015. Mr. Daly currently serves as President of CARsgen Therapeutics Corporation, an emerging oncology company focused on developing CAR-T therapies for both liquid and solid tumors. From July 2018 through January 2022, Mr. Daly served as Chief Operating Officer of BeyondSpring Pharmaceuticals, a pre-commercial biotech company focused on oncology with assets in late Phase 3 clinical trials. Before joining BeyondSpring in August 2018, (i) from February 2016 to July 2018 Mr. Daly served as Chairman and CEO of Neuralstem, Inc., a biopharmaceutical company focused on the development of central nervous system therapies based on its neuronal stem cell technology, (ii) from October 2014 to September 2016, Mr. Daly served as a partner of RavineRock Partners, a commercial consulting practice focused on biotech and pharmaceuticals, and (iii) from February 2013 to September 2014, Mr. Daly served as President of AstraZeneca US Diabetes. Mr. Daly served on the board of directors of Opiant Pharmaceuticals, and as a member of that board's Compensation and Audit Committees, from 2018 until the sale of that company in 2023. From June 2015 to June 2018 Mr. Daly also served on the Board of Directors of Synergy Pharmaceuticals, where he chaired the Nominations/Corporate Governance Committee and was a member of the Compensation Committee. Mr. Daly received his Bachelor of Science in Microbiology from the University of Notre Dame in 1983 and his MBA from the Kellogg School of Management, Northwestern University in 1998.

高管简历

中英对照 |  中文 |  英文
Patrick Griffin

Patrick Griffin自2015年1月19日以来担任我们的执行副总裁和首席医疗官(在他自2013年5月23日加入担任我们的高级副总裁和首席医疗官之前)。从2012年3月到2013年4月他担任临床开发的助理副总裁和外部创新主管。他从2010年1月至2012年2月担任Immusant, Inc.的首席医疗官和开发高级副总裁。他是内科和胃肠病学通过职业验证的医生,并且是美国医师学会(the American College of Physicians)会员。他获得Columbia University的医学学位,完成在纽约Presbyterian Hospital内科住院医生实习和波士顿Brigham and Women's Hospital胃肠病学的工作。在实习和工作后,他加入Columbia College of Physicians and Surgeons医疗职工群体,他在那里担任许多学术、临床研究、教学和管理职位,以及纽约个人私人诊所。


Patrick Griffin has served asthe company's Executive Vice President and Chief Medical Officer since January 19 2015 prior to which he served as our Senior Vice President and Chief Medical Officer since joining on May 23 2013. From March 2012 until April 2013 Dr Griffin served as Associate Vice President Clinical Development and Head of External Innovation. From January 2010 to Feb 2012 Dr. Griffin served as Chief Medical Officer and Senior Vice President Development at Immusant, Inc. He is a board-certified physician in both internal medicine and gastroenterology, and is a Fellow of the American College of Physicians. He received his medical degree from Columbia University, completing a residency in internal medicine at Presbyterian Hospital in New York, and a fellowship in gastroenterology at Brigham and Women’s Hospital in Boston. Following his residency and fellowship, Dr. Griffin joined the medical faculty of Columbia College of Physicians and Surgeons, where he held a number of academic, clinical research, teaching and management positions, as well as a solo private practice in New York.
Patrick Griffin自2015年1月19日以来担任我们的执行副总裁和首席医疗官(在他自2013年5月23日加入担任我们的高级副总裁和首席医疗官之前)。从2012年3月到2013年4月他担任临床开发的助理副总裁和外部创新主管。他从2010年1月至2012年2月担任Immusant, Inc.的首席医疗官和开发高级副总裁。他是内科和胃肠病学通过职业验证的医生,并且是美国医师学会(the American College of Physicians)会员。他获得Columbia University的医学学位,完成在纽约Presbyterian Hospital内科住院医生实习和波士顿Brigham and Women's Hospital胃肠病学的工作。在实习和工作后,他加入Columbia College of Physicians and Surgeons医疗职工群体,他在那里担任许多学术、临床研究、教学和管理职位,以及纽约个人私人诊所。
Patrick Griffin has served asthe company's Executive Vice President and Chief Medical Officer since January 19 2015 prior to which he served as our Senior Vice President and Chief Medical Officer since joining on May 23 2013. From March 2012 until April 2013 Dr Griffin served as Associate Vice President Clinical Development and Head of External Innovation. From January 2010 to Feb 2012 Dr. Griffin served as Chief Medical Officer and Senior Vice President Development at Immusant, Inc. He is a board-certified physician in both internal medicine and gastroenterology, and is a Fellow of the American College of Physicians. He received his medical degree from Columbia University, completing a residency in internal medicine at Presbyterian Hospital in New York, and a fellowship in gastroenterology at Brigham and Women’s Hospital in Boston. Following his residency and fellowship, Dr. Griffin joined the medical faculty of Columbia College of Physicians and Surgeons, where he held a number of academic, clinical research, teaching and management positions, as well as a solo private practice in New York.
Troy Hamilton

Troy Hamilton,2016年2月以来,他担任我们执行副总裁和首席商务官。从2015年7月到2016年2月,他担任我们高级副总裁和首席商务官。加入Synergy之前,他担任Shire Pharmaceuticals的多个商业领导职务9年。最后,他担任Shire的胃肠道GI业务部门的产品战略和商业领导副总裁。此前,他担任GI(比利时的两年的国际任务的一部分)国际营销副总裁。他担任炎症性肠病的全球特许经营(the Inflammatory Bowel Disease franchise globally)总经理。他于2006年加入Shire并担任美国营销负责人,成功领导Lialda 的投放市场并继续Pentasa 的商业化。此前,他在Johnson & Johnson的Janssen Pharmaceuticals和McNeil Specialty Products任职10年,担任许多GI/初级保健品牌管理、战略规划、新产品开发、和医疗服务的内部和实地领导职务。他获得费城the University of the Sciences的药店学士和药学博士学位以及St. Joseph’s University的工商管理硕士学位。


Troy Hamilton has served as the company's Executive Vice President, Chief Commercial Officer since February 2016 and as our Senior Vice President, Chief Commercial Officer from July 2015 to February 2016. Dr. Hamilton has over 20 years of experience in the pharmaceutical industry, with an emphasis on general management, P&L responsibility, commercialization, partnerships, acquisitions, and global product launches in the gastroenterology and primary care markets. Prior to joining Synergy, Dr. Hamilton held multiple commercial leadership roles over a nine year period at Shire Pharmaceuticals. Most recently, he was Vice President, Product Strategy and Commercial Lead for Shire’s Gastrointestinal GI Business Unit. Prior to this, he served as Vice President of GI International Marketing as part of a two year international assignment based in Belgium, and as General Manager for the Inflammatory Bowel Disease franchise globally. Dr. Hamilton joined Shire in 2006 as the Head of US Marketing, leading the successful launch of Lialda® and continued commercialization of Pentasa®. Previously, he spent 10 years at Johnson & Johnson’s Janssen Pharmaceuticals and McNeil Specialty Products in a number of in-house and field-based leadership roles within GI/primary care brand management, strategic planning, new product development, and medical services. Dr. Hamilton holds a BS in Pharmacy and PharmD from the University of the Sciences in Philadelphia and an MBA from St. Joseph’s University.
Troy Hamilton,2016年2月以来,他担任我们执行副总裁和首席商务官。从2015年7月到2016年2月,他担任我们高级副总裁和首席商务官。加入Synergy之前,他担任Shire Pharmaceuticals的多个商业领导职务9年。最后,他担任Shire的胃肠道GI业务部门的产品战略和商业领导副总裁。此前,他担任GI(比利时的两年的国际任务的一部分)国际营销副总裁。他担任炎症性肠病的全球特许经营(the Inflammatory Bowel Disease franchise globally)总经理。他于2006年加入Shire并担任美国营销负责人,成功领导Lialda 的投放市场并继续Pentasa 的商业化。此前,他在Johnson & Johnson的Janssen Pharmaceuticals和McNeil Specialty Products任职10年,担任许多GI/初级保健品牌管理、战略规划、新产品开发、和医疗服务的内部和实地领导职务。他获得费城the University of the Sciences的药店学士和药学博士学位以及St. Joseph’s University的工商管理硕士学位。
Troy Hamilton has served as the company's Executive Vice President, Chief Commercial Officer since February 2016 and as our Senior Vice President, Chief Commercial Officer from July 2015 to February 2016. Dr. Hamilton has over 20 years of experience in the pharmaceutical industry, with an emphasis on general management, P&L responsibility, commercialization, partnerships, acquisitions, and global product launches in the gastroenterology and primary care markets. Prior to joining Synergy, Dr. Hamilton held multiple commercial leadership roles over a nine year period at Shire Pharmaceuticals. Most recently, he was Vice President, Product Strategy and Commercial Lead for Shire’s Gastrointestinal GI Business Unit. Prior to this, he served as Vice President of GI International Marketing as part of a two year international assignment based in Belgium, and as General Manager for the Inflammatory Bowel Disease franchise globally. Dr. Hamilton joined Shire in 2006 as the Head of US Marketing, leading the successful launch of Lialda® and continued commercialization of Pentasa®. Previously, he spent 10 years at Johnson & Johnson’s Janssen Pharmaceuticals and McNeil Specialty Products in a number of in-house and field-based leadership roles within GI/primary care brand management, strategic planning, new product development, and medical services. Dr. Hamilton holds a BS in Pharmacy and PharmD from the University of the Sciences in Philadelphia and an MBA from St. Joseph’s University.
Marino Garcia

Marino Garcia, 2016年3月以来,他担任我们执行副总裁和首席战略官。从2014年3月到2016年3月,他担任我们高级副总裁,负责公司开发(2014年3月至2016年3月)。加入Synergy公司之前,他曾担任Aptalis Pharma(私营专业公司,专注于胃肠和囊性纤维,于2014年被Forest Labs收购)的全球商业开发副总裁。2006年至2010年,他曾担任Aspreva Pharmaceuticals(被Zurich-based Vifor Pharmaceuticals收购)的美国商业运营和新产品开发副总裁。职业生涯早期,他曾担任多家公司的多种美国和国际领导职务,并不断被提拔,其中包括Eli Lilly & Co、Pfizer。他持有Concordia University(位于魁北克蒙特利尔)的工商管理学士学位,以及the Richard Ivey School of Business at Western University(位于安大略省伦敦)工商管理硕士学位。


Marino Garcia has served as the company's Executive Vice President and Chief Strategy Officer since March 2016 and as our Senior Vice President - Corporate Development from March 2014 to March 2016. Mr. Garcia has over 20 years of experience in various commercial, new product planning and business development roles. Prior to joining Synergy, Mr. Garcia served as Vice President of Global Business Development at Aptalis Pharma, a privately held specialty company focused on the gastrointestinal and cystic fibrosis markets which was acquired by Forest Labs in early 2014. From 2006 to 2010 Mr. Garcia served as Vice President of US Commercial Operations and New Product Development at Aspreva Pharmaceuticals, which was acquired by Zurich-based Vifor Pharmaceuticals. Earlier in his career, Mr. Garcia served in various U.S. and international leadership roles of increasing responsibility in companies like Eli Lilly & Co and Pfizer. Mr. Garcia received a Bachelor’s Degree in Business Administration from Concordia University in Montreal, Quebec, and an M.B.A. from the Richard Ivey School of Business at Western University in London, Ontario.
Marino Garcia, 2016年3月以来,他担任我们执行副总裁和首席战略官。从2014年3月到2016年3月,他担任我们高级副总裁,负责公司开发(2014年3月至2016年3月)。加入Synergy公司之前,他曾担任Aptalis Pharma(私营专业公司,专注于胃肠和囊性纤维,于2014年被Forest Labs收购)的全球商业开发副总裁。2006年至2010年,他曾担任Aspreva Pharmaceuticals(被Zurich-based Vifor Pharmaceuticals收购)的美国商业运营和新产品开发副总裁。职业生涯早期,他曾担任多家公司的多种美国和国际领导职务,并不断被提拔,其中包括Eli Lilly & Co、Pfizer。他持有Concordia University(位于魁北克蒙特利尔)的工商管理学士学位,以及the Richard Ivey School of Business at Western University(位于安大略省伦敦)工商管理硕士学位。
Marino Garcia has served as the company's Executive Vice President and Chief Strategy Officer since March 2016 and as our Senior Vice President - Corporate Development from March 2014 to March 2016. Mr. Garcia has over 20 years of experience in various commercial, new product planning and business development roles. Prior to joining Synergy, Mr. Garcia served as Vice President of Global Business Development at Aptalis Pharma, a privately held specialty company focused on the gastrointestinal and cystic fibrosis markets which was acquired by Forest Labs in early 2014. From 2006 to 2010 Mr. Garcia served as Vice President of US Commercial Operations and New Product Development at Aspreva Pharmaceuticals, which was acquired by Zurich-based Vifor Pharmaceuticals. Earlier in his career, Mr. Garcia served in various U.S. and international leadership roles of increasing responsibility in companies like Eli Lilly & Co and Pfizer. Mr. Garcia received a Bachelor’s Degree in Business Administration from Concordia University in Montreal, Quebec, and an M.B.A. from the Richard Ivey School of Business at Western University in London, Ontario.
Patrick Griffin

Patrick Griffin于2019年2月成为我们的首席医疗官。此前,格里芬博士曾于2015年1月至2018年11月担任Synergy Pharmaceuticals执行Vice President兼首席医疗官,并于2013年5月至2015年1月担任高级副总裁兼首席医疗官。2012年3月至2013年4月,Griffin博士担任Immusant,Inc.的首席医疗官兼发展高级副总裁。从2009年3月到2012年1月,Griffin博士担任赛诺菲-安万特(Sanofi-Aventis)(现为赛诺菲)临床开发副Vice President和外部创新主管。他是内科和胃肠病学的董事会认证医师,也是the American College of Physicians的院士。他在哥伦比亚大学(Columbia University)获得医学学位,在纽约长老会医院(Presbyterian Hospital)完成内科住院医师学位,在波士顿布莱根妇女医院(Brigham and Women’s Hospital)获得消化内科奖学金。在他的住院医师和奖学金之后,Griffin博士加入Columbia College of Physicians and Surgeons的医学院,在那里他担任多个学术,临床研究,教学和管理职位,并在纽约保持私人执业。


Patrick Griffin became our Chief Medical Officer in February 2019. Previously Dr. Griffin served as Executive Vice President and Chief Medical Officer of Synergy Pharmaceuticals from January 2015 through November 2018 and Senior Vice President and Chief Medical Officer from May 2013 through January 2015. From March 2012 to April 2013 Dr. Griffin served as Chief Medical Officer and Senior Vice President of Development at ImmusanT, Inc. From March 2009 until January 2012 Dr. Griffin served as Associate Vice President, Clinical Development and Head of External Innovation at Sanofi-Aventis now Sanofi. He is a board-certified physician in both internal medicine and gastroenterology, and is a Fellow of the American College of Physicians. He received his medical degree from Columbia University, completing a residency in internal medicine at Presbyterian Hospital in New York, and a fellowship in gastroenterology at Brigham and Women's Hospital in Boston. Following his residency and fellowship, Dr. Griffin joined the medical faculty of Columbia College of Physicians and Surgeons, where he held a number of academic, clinical research, teaching and management positions, and maintained a private practice in New York.
Patrick Griffin于2019年2月成为我们的首席医疗官。此前,格里芬博士曾于2015年1月至2018年11月担任Synergy Pharmaceuticals执行Vice President兼首席医疗官,并于2013年5月至2015年1月担任高级副总裁兼首席医疗官。2012年3月至2013年4月,Griffin博士担任Immusant,Inc.的首席医疗官兼发展高级副总裁。从2009年3月到2012年1月,Griffin博士担任赛诺菲-安万特(Sanofi-Aventis)(现为赛诺菲)临床开发副Vice President和外部创新主管。他是内科和胃肠病学的董事会认证医师,也是the American College of Physicians的院士。他在哥伦比亚大学(Columbia University)获得医学学位,在纽约长老会医院(Presbyterian Hospital)完成内科住院医师学位,在波士顿布莱根妇女医院(Brigham and Women’s Hospital)获得消化内科奖学金。在他的住院医师和奖学金之后,Griffin博士加入Columbia College of Physicians and Surgeons的医学院,在那里他担任多个学术,临床研究,教学和管理职位,并在纽约保持私人执业。
Patrick Griffin became our Chief Medical Officer in February 2019. Previously Dr. Griffin served as Executive Vice President and Chief Medical Officer of Synergy Pharmaceuticals from January 2015 through November 2018 and Senior Vice President and Chief Medical Officer from May 2013 through January 2015. From March 2012 to April 2013 Dr. Griffin served as Chief Medical Officer and Senior Vice President of Development at ImmusanT, Inc. From March 2009 until January 2012 Dr. Griffin served as Associate Vice President, Clinical Development and Head of External Innovation at Sanofi-Aventis now Sanofi. He is a board-certified physician in both internal medicine and gastroenterology, and is a Fellow of the American College of Physicians. He received his medical degree from Columbia University, completing a residency in internal medicine at Presbyterian Hospital in New York, and a fellowship in gastroenterology at Brigham and Women's Hospital in Boston. Following his residency and fellowship, Dr. Griffin joined the medical faculty of Columbia College of Physicians and Surgeons, where he held a number of academic, clinical research, teaching and management positions, and maintained a private practice in New York.
Gary G. Gemignani

Gary G. Gemignani,2014年9月加入公司。他在生命科学行业的会计、策略规划和财务上拥有超过25年的工作经验。并且他曾任诺华(Novartis)、美国保德信金融集团(Prudential Financial)、惠氏(Wyeth)和安达信会计师事务所(Arthur Andersen)担任高级领导和管理职位。2011年至2013年他曾任职于Champions Oncology,担任首席财务官兼执行副总裁,负责集资、投资者关系和财务运作。2010年至2011年,他担任Coronado Biosciences Inc.的执行副总裁、首席营运官和首席财务官,负责财务运作、策略规划和业务开发活动。2006年至2010年,他也曾担任Gentium S.P.A的执行副总裁、首席营运官和首席财务官。他取得了圣彼得学院(St. Peter's College)会计学士学位。


Gary G. Gemignani has served as the company's Executive Vice President and Chief Financial Officer since April 2017 From 2014 until 2016 Mr. Gemignani was Chief Financial Officer of Biodel, Inc. and assumed the role of interim Chief Executive Officer in January 2016 until November 2016. From 2013 to 2014 Mr. Gemignani was a consultant to TNI Biotechnology. From 2011 to 2013 Mr. Gemignani was Executive Vice President and Chief Financial Officer of Champions Oncology, Inc. From 2010 to 2011 Mr. Gemignani was Executive Vice President, Chief Operating Officer and Chief Financial Officer of Coronado Biosciences, Inc. and from 2006 to 2010 Mr. Gemignani was Executive Vice President and Chief Financial Officer of Gentium S.p.A.
Gary G. Gemignani,2014年9月加入公司。他在生命科学行业的会计、策略规划和财务上拥有超过25年的工作经验。并且他曾任诺华(Novartis)、美国保德信金融集团(Prudential Financial)、惠氏(Wyeth)和安达信会计师事务所(Arthur Andersen)担任高级领导和管理职位。2011年至2013年他曾任职于Champions Oncology,担任首席财务官兼执行副总裁,负责集资、投资者关系和财务运作。2010年至2011年,他担任Coronado Biosciences Inc.的执行副总裁、首席营运官和首席财务官,负责财务运作、策略规划和业务开发活动。2006年至2010年,他也曾担任Gentium S.P.A的执行副总裁、首席营运官和首席财务官。他取得了圣彼得学院(St. Peter's College)会计学士学位。
Gary G. Gemignani has served as the company's Executive Vice President and Chief Financial Officer since April 2017 From 2014 until 2016 Mr. Gemignani was Chief Financial Officer of Biodel, Inc. and assumed the role of interim Chief Executive Officer in January 2016 until November 2016. From 2013 to 2014 Mr. Gemignani was a consultant to TNI Biotechnology. From 2011 to 2013 Mr. Gemignani was Executive Vice President and Chief Financial Officer of Champions Oncology, Inc. From 2010 to 2011 Mr. Gemignani was Executive Vice President, Chief Operating Officer and Chief Financial Officer of Coronado Biosciences, Inc. and from 2006 to 2010 Mr. Gemignani was Executive Vice President and Chief Financial Officer of Gentium S.p.A.
Kunwar Shailubhai

Kunwar Shailubhai,2008年7月起担任公司首席科学官。2004年3月至2008年7月,他担任Synergy DE药物开发部高级副总裁。2003年5月至2004年3月,他担任Synergy DE研发部执行副总裁。2001至2003年4月,他担任Synergy DE药物开发部副总裁,主要负责临床前开发治疗结肠癌和胃肠道炎症药物的GC-C激动剂项目。1993至2000年,他在Monsanto Company担任癌症化学预防组的负责人。他之前在国立卫生研究院(National Institutes of Health)担任高级教员,且在University of Maryland担任助理教授。他1984年获得印度University of Baroda微生物学博士学位,2001年获得圣路易斯University of Missouri的工商管理硕士学位。


Kunwar Shailubhai has served as Chief Executive Officer, Chief Scientific Officer and Executive Director of the company since 2008. Since April, 2017 Dr. Shailubhai has served as Chief Executive Officer of Rasna Therapeutics, Inc. Dr. Shailubhai was a co-founder of Synergy Pharmaceuticals Inc. and served as Chief Scientific Officer from July 2008 to May 2017. From March 2004 until July 2008 Dr. Shailubhai served as Senior Vice President, Drug Discovery of Synergy, which at that time was a subsidiary of Callisto Pharmaceuticals, Inc. “Synergy DE”. From May 2003 until March 2004 Dr. Shailubhai served as executive vice president, R&D of Synergy DE. From 2001 to April 2003 Dr. Shailubhai held the position of Vice President, Drug Discovery at Synergy DE where he was chiefly responsible for the preclinical development of its GC-C agonist program for drugs to treat colon cancer and GI inflammation. Between 1993 and 2000 he was with Monsanto Company, serving as group leader of the cancer chemoprevention group. Dr. Shailubhai previously served as a senior staff fellow at the National Institutes of Health, and as an assistant professor at the University of Maryland. Dr. Shailubhai received his Ph.D. in microbiology in 1984 from the University of Baroda, India, and his MBA in 2001 from the University of Missouri, St. Louis.
Kunwar Shailubhai,2008年7月起担任公司首席科学官。2004年3月至2008年7月,他担任Synergy DE药物开发部高级副总裁。2003年5月至2004年3月,他担任Synergy DE研发部执行副总裁。2001至2003年4月,他担任Synergy DE药物开发部副总裁,主要负责临床前开发治疗结肠癌和胃肠道炎症药物的GC-C激动剂项目。1993至2000年,他在Monsanto Company担任癌症化学预防组的负责人。他之前在国立卫生研究院(National Institutes of Health)担任高级教员,且在University of Maryland担任助理教授。他1984年获得印度University of Baroda微生物学博士学位,2001年获得圣路易斯University of Missouri的工商管理硕士学位。
Kunwar Shailubhai has served as Chief Executive Officer, Chief Scientific Officer and Executive Director of the company since 2008. Since April, 2017 Dr. Shailubhai has served as Chief Executive Officer of Rasna Therapeutics, Inc. Dr. Shailubhai was a co-founder of Synergy Pharmaceuticals Inc. and served as Chief Scientific Officer from July 2008 to May 2017. From March 2004 until July 2008 Dr. Shailubhai served as Senior Vice President, Drug Discovery of Synergy, which at that time was a subsidiary of Callisto Pharmaceuticals, Inc. “Synergy DE”. From May 2003 until March 2004 Dr. Shailubhai served as executive vice president, R&D of Synergy DE. From 2001 to April 2003 Dr. Shailubhai held the position of Vice President, Drug Discovery at Synergy DE where he was chiefly responsible for the preclinical development of its GC-C agonist program for drugs to treat colon cancer and GI inflammation. Between 1993 and 2000 he was with Monsanto Company, serving as group leader of the cancer chemoprevention group. Dr. Shailubhai previously served as a senior staff fellow at the National Institutes of Health, and as an assistant professor at the University of Maryland. Dr. Shailubhai received his Ph.D. in microbiology in 1984 from the University of Baroda, India, and his MBA in 2001 from the University of Missouri, St. Louis.
Bernard F. Denoyer

Bernard F. Denoyer,2008年7月起任公司财务高级副总裁和秘书。2013年5月起,担任公司前全资子公司、生物制药研发公司ContraVir Pharmaceuticals, Inc.的首席财务官。2007年12月至2013年1月,担任Callisto Pharmaceuticals, Inc.财务高级副总裁和秘书。2004年1月至2007年11月担任Callisto的财务副总裁和秘书。2000年10月至2003年12月,担任独立顾问,担任新兴科技公司的临时首席财务官和提供其他服务,包括Callisto、Marsh & McLennan Capital, LLC的投资组合公司在内。1994年10月至2000年9月,他担任公共信息技术研究公司META Group, Inc.的首席财务官和高级副总裁,协助该公司1995年首次上市发行。1990至1993年,他担任Environetics, Inc.的财务副总裁,该公司从事制药水诊断测试业务,后被IDEXX Laboratories, Inc.收购。


Bernard F. Denoyer has served as the company's Senior Vice President, Finance and Secretary since July 2008. From December 2007 until January 2013 Mr. Denoyer served as Senior Vice President, Finance and Secretary of Callisto Pharmaceuticals, Inc.and from January 2004 to November 2007 Mr. Denoyer served as Callisto’s Vice President, Finance and Secretary. From October 2000 to December 2003 Mr. Denoyer was an independent consultant providing interim CFO and other services to emerging technology companies, including Callisto and certain portfolio companies of Marsh & McLennan Capital, LLC. From October 1994 until September 2000 Mr. Denoyer served as Chief Financial Officer and Senior Vice President at META Group, Inc., a public information technology research company, where he was instrumental in their 1995 IPO. From 1990 to 1993 he served as Vice President, Finance of Environetics, Inc., a pharmaceutical water diagnostic test business, acquired by IDEXX Laboratories, Inc. Mr. Denoyer received his bachelor’s degree in Economics from Fairfield University, his M.B.A. in Finance from Columbia Business School and earned his CPA while with Ernst & Young.
Bernard F. Denoyer,2008年7月起任公司财务高级副总裁和秘书。2013年5月起,担任公司前全资子公司、生物制药研发公司ContraVir Pharmaceuticals, Inc.的首席财务官。2007年12月至2013年1月,担任Callisto Pharmaceuticals, Inc.财务高级副总裁和秘书。2004年1月至2007年11月担任Callisto的财务副总裁和秘书。2000年10月至2003年12月,担任独立顾问,担任新兴科技公司的临时首席财务官和提供其他服务,包括Callisto、Marsh & McLennan Capital, LLC的投资组合公司在内。1994年10月至2000年9月,他担任公共信息技术研究公司META Group, Inc.的首席财务官和高级副总裁,协助该公司1995年首次上市发行。1990至1993年,他担任Environetics, Inc.的财务副总裁,该公司从事制药水诊断测试业务,后被IDEXX Laboratories, Inc.收购。
Bernard F. Denoyer has served as the company's Senior Vice President, Finance and Secretary since July 2008. From December 2007 until January 2013 Mr. Denoyer served as Senior Vice President, Finance and Secretary of Callisto Pharmaceuticals, Inc.and from January 2004 to November 2007 Mr. Denoyer served as Callisto’s Vice President, Finance and Secretary. From October 2000 to December 2003 Mr. Denoyer was an independent consultant providing interim CFO and other services to emerging technology companies, including Callisto and certain portfolio companies of Marsh & McLennan Capital, LLC. From October 1994 until September 2000 Mr. Denoyer served as Chief Financial Officer and Senior Vice President at META Group, Inc., a public information technology research company, where he was instrumental in their 1995 IPO. From 1990 to 1993 he served as Vice President, Finance of Environetics, Inc., a pharmaceutical water diagnostic test business, acquired by IDEXX Laboratories, Inc. Mr. Denoyer received his bachelor’s degree in Economics from Fairfield University, his M.B.A. in Finance from Columbia Business School and earned his CPA while with Ernst & Young.
Gary S. Jacob

Gary S. Jacob。 Gary S. Jacob博士自2009年2月起担任公司董事。自2008年7月以来,Jacob博士一直担任Synergy Pharmaceuticals Inc.的总裁,首席执行官和董事,并担任该公司的董事。 主席自2013年9月起。雅各布博士自2013年5月起担任ContraVir Pharmaceuticals,Inc.的董事长。雅各博士于2004年10月起担任Callisto Pharmaceuticals,Inc.的董事,直至2013年1月与Synergy Pharmaceuticals,Inc.合并。 1999年之前,Jacob博士担任孟山都科学研究员,专攻糖生物学领域,1997年至1998年,他担任孟山都公司的功能基因组学,企业科学与技术总监。 雅各博士获得了B.S。 在密苏里大学化学,并拥有博士学位。 来自威斯康星大学麦迪逊分校的生物化学专业。


Gary S. Jacob,has served as Chief Executive Officer and a director of Okyo Pharma Limited since January 2021. From November 2018 to March 2020, Dr. Jacob was the Chief Executive Officer of Immuron Limited, an Australian microbiome biopharmaceutical company. From July 2008 until December 2017, Dr. Jacob was President and Chief Executive Officer of Synergy Pharmaceuticals Inc., a biopharmaceutical company, where he held various positions from July 2008 to November 2018 and he served as its Chairman from September 2013 to November 2018. On December 12, 2018, Synergy Pharmaceuticals Inc. filed a petition for relief under Chapter 11 of the U.S. Bankruptcy Code. Since March 19, 2014, Dr. Jacob has been Chairman of the Board of Hepion Pharmaceuticals, Inc., a biotechnology company, and earlier served as its Chief Executive Officer from May 15, 2013 until March 19, 2014. Dr. Jacob served as Chief Executive Officer of Callisto Pharmaceuticals, Inc. from May 2003 until January 2013 and a director from October 2004 until January 2013. Dr. Jacob also serves as a director of Rasna Therapeutics, Inc., and is a past director of Cardiff Oncology, Inc. Dr. Jacob has over 35 years of experience in the pharmaceutical and biotechnology industries across multiple disciplines including research & development, operations and business development. Prior to 1999, Dr. Jacob served as a Monsanto Science Fellow, specializing in the field of glycobiology, and from 1997 to 1998 Dr. Jacob was Director of Functional Genomics, Corporate Science & Technology, at Monsanto Company. Dr. Jacob also served from 1990 to 1997 as Director of Glycobiology at G.D. Searle Pharmaceuticals Inc. During the period of 1986 to 1990, he was Manager of the G.D. Searle Glycobiology Group at Oxford University, England.
Gary S. Jacob。 Gary S. Jacob博士自2009年2月起担任公司董事。自2008年7月以来,Jacob博士一直担任Synergy Pharmaceuticals Inc.的总裁,首席执行官和董事,并担任该公司的董事。 主席自2013年9月起。雅各布博士自2013年5月起担任ContraVir Pharmaceuticals,Inc.的董事长。雅各博士于2004年10月起担任Callisto Pharmaceuticals,Inc.的董事,直至2013年1月与Synergy Pharmaceuticals,Inc.合并。 1999年之前,Jacob博士担任孟山都科学研究员,专攻糖生物学领域,1997年至1998年,他担任孟山都公司的功能基因组学,企业科学与技术总监。 雅各博士获得了B.S。 在密苏里大学化学,并拥有博士学位。 来自威斯康星大学麦迪逊分校的生物化学专业。
Gary S. Jacob,has served as Chief Executive Officer and a director of Okyo Pharma Limited since January 2021. From November 2018 to March 2020, Dr. Jacob was the Chief Executive Officer of Immuron Limited, an Australian microbiome biopharmaceutical company. From July 2008 until December 2017, Dr. Jacob was President and Chief Executive Officer of Synergy Pharmaceuticals Inc., a biopharmaceutical company, where he held various positions from July 2008 to November 2018 and he served as its Chairman from September 2013 to November 2018. On December 12, 2018, Synergy Pharmaceuticals Inc. filed a petition for relief under Chapter 11 of the U.S. Bankruptcy Code. Since March 19, 2014, Dr. Jacob has been Chairman of the Board of Hepion Pharmaceuticals, Inc., a biotechnology company, and earlier served as its Chief Executive Officer from May 15, 2013 until March 19, 2014. Dr. Jacob served as Chief Executive Officer of Callisto Pharmaceuticals, Inc. from May 2003 until January 2013 and a director from October 2004 until January 2013. Dr. Jacob also serves as a director of Rasna Therapeutics, Inc., and is a past director of Cardiff Oncology, Inc. Dr. Jacob has over 35 years of experience in the pharmaceutical and biotechnology industries across multiple disciplines including research & development, operations and business development. Prior to 1999, Dr. Jacob served as a Monsanto Science Fellow, specializing in the field of glycobiology, and from 1997 to 1998 Dr. Jacob was Director of Functional Genomics, Corporate Science & Technology, at Monsanto Company. Dr. Jacob also served from 1990 to 1997 as Director of Glycobiology at G.D. Searle Pharmaceuticals Inc. During the period of 1986 to 1990, he was Manager of the G.D. Searle Glycobiology Group at Oxford University, England.